MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in public...
$593,957K
Proceeds from issuance of
long-term debt, net of...
$148,256K
Proceeds from issuance of
common stock in...
$140,653K
Proceeds from exercise of
stock options
$7,999K
Net cash provided by
financing activities
$890,307K
Canceled cashflow
$558K
Net increase
(decrease) in cash, cash...
$458,349K
Canceled cashflow
$431,958K
Payment of debt issuance
costs
$558K
Stock-based compensation
expense
$45,851K
Accounts payable and
other liabilities
$8,251K
Depreciation and
amortization expense
$2,049K
Prepaid expenses and
other current assets
-$986K
Non-cash lease expense
$163K
Non-cash interest
expense
$118K
Loss on disposal of
property and equipment
-$95K
Maturities of marketable
securities
$154,642K
Sales of marketable
securities
$17,851K
Net cash used in
operating activities
-$403,207K
Net cash (used in)
provided by investing...
-$28,751K
Canceled cashflow
$57,513K
Canceled cashflow
$172,493K
Net loss
-$446,214K
Purchases of marketable
securities
$180,534K
Other non-current
assets
$12,641K
Accretion of discount on
marketable securities
-$1,835K
Loss (gain) on sale of
marketable securities
-$30K
Advance payment for
long-lead equipment
$18,790K
Purchases of property and
equipment
$1,920K
Back
Back
Cash Flow
source: myfinsight.com
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)